Shares of companies specializing in psychedelic-related therapies experienced a dramatic surge in premarket trading on Monday, following the signing of an executive order by U.S. President Donald Trump aimed at accelerating research and access to these treatments. This development has ignited investor optimism, marking a potential turning point for the burgeoning industry.
Market Reaction and Key Players
In response to the news, U.S.-traded stocks of leading psychedelic firms saw significant gains. Compass Pathways Plc led the charge with a spike of up to 39 percent before the market opened, while AtaiBeckley Inc. surged 32 percent. Definium Therapeutics, Inc. rallied 27 percent, and GH Research PLC jumped 20 percent, reflecting widespread market enthusiasm.
Details of the Executive Order
The executive order, signed by President Trump on April 18, 2026, in the Oval Office, directs the U.S. Food and Drug Administration to issue expedited review vouchers for psychedelics that have received a breakthrough designation. This move is expected to shorten the review timeline from the typical six to ten months down to just one to two months, significantly speeding up the approval process for promising therapies.
Notably, companies such as AtaiBeckley, Definium Therapeutics, and Compass Pathways all have therapies that currently hold breakthrough designation status, positioning them to benefit directly from this regulatory shift.
Industry Implications and Analyst Insights
For Wall Street, this executive order represents a pivotal moment for the psychedelic industry, which has long awaited a breakthrough to gain mainstream acceptance. Analysts view the support from the highest levels of the U.S. government as a crucial step in easing the approval pathway for drug developers, thereby reducing regulatory risks.
In a note to clients, RBC Capital Markets analyst Brian Abrahams emphasized that the order is "a substantial step towards diminishing regulatory risk in this emerging class of therapies, enabling investor comfort." He added, "While not explicitly recommending psychedelics, the nature of the executive order strongly suggests a broad openness to psychedelics."
Focus on Specific Compounds and Past Setbacks
The order also includes directives for the FDA to provide new guidance to researchers on ibogaine, a psychedelic compound derived from the iboga plant in Africa. Ibogaine is being studied for its potential to treat conditions such as depression, anxiety, and post-traumatic stress disorder, particularly among military veterans. Although the order does not reclassify the drug for medical use, President Trump urged health professionals to expedite this reclassification.
This development comes after a significant setback in 2024, when U.S. regulators rejected an MDMA-assisted therapy for PTSD from Lykos Therapeutics Inc., citing concerns over research quality and clinical trial design. The new executive order aims to address such hurdles by streamlining the regulatory framework.
Future Outlook and Investor Sentiment
Looking ahead, analysts are optimistic about the industry's prospects. Jefferies analyst Andrew Tsai noted in a research note that "With several executive branches aligned, investor mindshare should rise meaningfully ahead of potential approvals in 2027-2030." This sentiment underscores the growing confidence that the psychedelic sector could see accelerated growth and broader acceptance in the coming years.
The surge in stock prices and the regulatory advancements signal a transformative phase for psychedelic therapies, potentially paving the way for innovative treatments in mental health and beyond.
